Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sensitizing EGFR Gene Mutation”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Testing effectiveness (Phase 2)Study completedNCT00997334
What this trial is testing

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer
David M. Jackman, MD 60
Testing effectiveness (Phase 2)UnknownNCT04405674
What this trial is testing

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT05786430
What this trial is testing

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 87
Testing effectiveness (Phase 2)UnknownNCT03382795
What this trial is testing

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Korea University Guro Hospital 63
Not applicableLooking for participantsNCT01994057
What this trial is testing

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06563999
What this trial is testing

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Who this might be right for
Lung Cancer Stage IIIMutation
Sun Yat-sen University 120
Testing effectiveness (Phase 2)Study completedNCT06521034
What this trial is testing

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Sensitizing Mutation
Yongchang Zhang 124
Early research (Phase 1)Study completedNCT03846310
What this trial is testing

Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of Lung+1 more
Arcus Biosciences, Inc. 77
Not applicableUnknownNCT04930133
What this trial is testing

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

Who this might be right for
NSCLC
Seoul St. Mary's Hospital 737
Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40
Not applicableUnknownNCT02661009
What this trial is testing

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Who this might be right for
Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation
GenoSaber 1,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07551414
What this trial is testing

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Who this might be right for
NSCLC (Non-small Cell Lung Carcinoma)Leptomeningeal MetastasisEGFR-TKI Sensitizing Mutation+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 38
Testing effectiveness (Phase 2)UnknownNCT01410214
What this trial is testing

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer Stage IIIA
Chinese Lung Cancer Surgical Group 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07298148
What this trial is testing

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Who this might be right for
NSCLC Stage IVEGFR Positive Non-small Cell Lung CancerEGFR-TKI Sensitizing Mutation
Peking University Cancer Hospital & Institute 28
Large-scale testing (Phase 3)UnknownNCT01407822
What this trial is testing

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 72
Large-scale testing (Phase 3)Looking for participantsNCT06970639
What this trial is testing

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Who this might be right for
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc. 380
Testing effectiveness (Phase 2)Active Not RecruitingNCT03786692
What this trial is testing

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Who this might be right for
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Fox Chase Cancer Center 107
Not applicableStudy completedNCT05862194
What this trial is testing

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Yuhan Corporation 534
Large-scale testing (Phase 3)Active Not RecruitingNCT03833154
What this trial is testing

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 724
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Load More Results